Analysis of antidepressants effectiveness in adolescents: InfoPOEMs podcast
Essential Evidence Plus, formerly InfoPOEMs is a service by John Wiley and Sons that aims to give physicians succinct medical evidence that will impact in their medical practice. In this podcast Dr. Ebell and Dr. Wilkes (National Public Radio) discuss the POEM titled: “Antidepressants only modestly effective for adolescent depression” Listen to the podcast on […]
NPS: Desvenlafaxine (Pristiq) not superior to venlafaxine for major depressive disorder
The National Prescribing Service Limited (Australia) made an independent evaluation on the role of desvenlafaxine (Pristiq) for the treatment of major depressive disorder. Summary: Desvenlafaxine is the active metabolite of venlafaxine. There is no evidence that desvenlafaxine is more effective, safer or better tolerated than venlafaxine or other antidepressants. Doses above 50 mg/day are unlikely […]
Atomoxetine (Strattera) for ADHD: risk of psychotic or manic symptoms
The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for March 2009. One of the drugs reviewed is atomoxetin (Strattera), a norepinephrine reuptake inhibitor used for the treatment of ADHD. These are the recommendations: Advice for healthcare professionals: • At normal doses, atomoxetine can be associated with treatment-emergent psychotic or manic […]
Duloxetine (Cymbalta, Yentreve): a serotonin-norepinephrine reuptake inhibitor for major depression. Australian prescriber review
From Australian Prescriber: Duloxetine Cymbalta (Eli Lilly) 30 mg and 60 mg capsules Approved indication: major depression Australian Medicines Handbook section 18.1.2 Duloxetine is a new antidepressant which selectively inhibits serotonin and noradrenaline reuptake. It also weakly inhibits dopamine uptake. (See details of its mechanism of action)
SSRIs, SNRIs and SSNRIs: clinical guideline by the ACP
The American College of Physicians has issued a Clinical Practice Guideline about the use of Second-Generation Antidepressants in the treatment of Depressive Disorders. The recommendations that arise from it are the following: Recommendation 1: The American College of Physicians recommends that when clinicians choose pharmacologic therapy to treat patients with acute major depression, they select […]